Galatea Bio is a biotechnology company committed to driving groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research. We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests and treatments that will improve the lives of all.
Status: Private
Comanche Biopharma
Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to lower the risks of pregnancy and premature births worldwide. We are currently developing the world’s first treatment for preeclampsia, which affects more than 10 million women every year.
Alternative Bio (ABio)
Alternative Bio’s mission is to translate the discovery of novel protein synthesis regulatory nodes into first-in-class precision medicines to treat the most challenging cancers. The company’s vision is to establish itself as a global pioneer in this new research space as it advances breakthrough therapies to benefit cancer patients worldwide.
Deal Engine
Deal Engine is a travel software company with a mission to bring digital transformation to the travel industry. Utilizing proprietary AI and APIs, Deal Engine brings automation to travel, eliminating manual processes, and making sure people spend their time where they generate more value.
Zeen Health
Zeen Health is a health IT company developing prescription digital therapeutics (PDT) for various mental health disorders.
FCB Health
FCB Health is a health insurance and services company that aims to resolve the longstanding financial burden of rising medical expenses in rural China. FCB Health was acquired by Interpublic Group (IPG).
NeuroSmart
NeuroSmart is an operator of an education and research center focusing on autism. The company helps patients with autism through scientific research and early intervention application, providing families with a comprehensive scientific family intervention program.
Elucidata
Elucidata was founded in 2015 by University of Chicago and MIT graduate Dr. Abhishek Jha and IIT Delhi alumnus Swetabh Pathak. The company’s cutting-edge platform Polly operates on unique Bio-NLP technology that cleans, and links 26+ R&D data types and caters to companies in various stages of their drug discovery process. The platform helps data science teams scale by providing them 70 TB of ML-Ready biomedical data, from ~30 public and proprietary sources. Today, 3 of the top 10 pharmaceutical companies are using Polly to fast track their R&D initiatives.
RIGImmune
RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The RIGImmune development candidates act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The lead development candidate at RIGImmune is RIG-101.
The company was co-founded by the prominent Yale University professors, Anna Marie Pyle, Ph.D. and Akiko Iwasaki, Ph.D., who currently serve as scientific advisors to the company. Dr. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on the cytosolic protein, RIG-I. Dr. Pyle is also a specialist in RNA structure and design. She designed the stem-loop RNA therapeutics (SLR) for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds in collaboration with Dr. Iwasaki, whose expertise in mucosal immunity has been highly sought during the COVID-19 pandemic.
RIGImmune is a UConn Technology Incubation Program (TIP) company located in Farmington, CT, was founded by Yale scientists, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists.
Ashby
Ashby exists to deliver a new standard of recruiting software to enable hiring excellence. It’s all-in-one recruiting platform enables high growth companies to hire more efficiently by combining features for the entire recruiting process, from sourcing to offer, with advanced analytics and automation.